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Purpose: Gastric carcinoma tissues release high level of
prostaglandin E2 (PGE2) when compared to non-neoplastic
mucosa, and cyclooxygenase-2 (COX-2), which is the rate-
limiting enzyme in prostaglandin (PG) biosynthesis, is often
overexpressed in gastric carcinomas and during gastric
carcinogenesis. However, little is known about the expression
of 15-hydroxyprostaglandin dehydrogenase (15-PGDH), the
key enzyme responsible for the biological inactivation of PG,
in gastric carcinomas. Materials and Methods: We investigated
the expression of 15-PGDH in 28 cases of advanced gastric
carcinomas by Western blot analysis and also the relation
between its expression and the gene promoter methylation.
Results: 15-PGDH expression was significantly decreased in
gastric carcinomas compared to corresponding non-neoplastic
tissues and inversely correlated with the expression of pro-
liferating cell nuclear antigen in gastric carcinomas. However,
there was no correlation between 15-PGDH expression and
pathological findings such as nodal metastasis and vascular
invasion. Promoter hypermethylation of 15-PGDH gene was
not detected in carcinomas, with only a negligible expression
of the enzyme. Conclusion: Our results suggested that 15-
PGDH has tumor suppressor activity in gastric carcinomas.
Key Words: 15-hydroxyprostaglandin dehydrogenase, gastric
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INTRODUCTION
Prostaglandin E2 (PGE2) is a major prostanoid
in gastric tissue and involved in various physio-
logic and pathologic functions of gastric mucosal
cells.
1 Gastric carcinoma tissues release high level
of PGE2 compared to non-neoplastic mucosa.
2
PGE2 is related to carcinogenesis through immu-
nosuppression, inhibition of apoptosis, increase of
metastatic potential of epithelial cells and pro-
motion of angiogenesis.
3-7 Overexpression of cyclo-
oxygenase-2 (COX-2), the rate-limiting enzyme in
prostaglandin (PG) biosynthesis, can be found in
gastric carcinomas and during gastric carcino-
genesis.
8-11 PGs are rapidly metabolized by oxida-
tion of 15(S)-hydroxyl group of PGs which is
catalyzed by NAD+-linked 15-hydroxyprostaglan-
din dehydrogenase (15-PGDH).
12 Recent studies
identified a tumor suppressor activity of 15-PGDH
in colon, lung, and breast carcinomas and sug-
gested epigenetic silencing of the enzyme by DNA
methylation and histone modification.
13-17 How-
ever, little is known about the expression of 15-
PGDH in gastric carcinoma. Moreover, the result
of 15-PGDH expression in gastric carcinoma is
controversial. One study reported that 15-PGDH
expression was not altered in gastric carcinomas.
18
On the other hand, 15-PGDH was found to be
dysregulated in gastric carcinomas.
14 Here, we
investigated the expression of 15-PGDH in gastric
carcinomas and their non-neoplastic tissues, and
found that 15-PGDH expression was decreased in
gastric carcinomas.
MATERIALS AND METHODS
Tissue samples
We used 28 frozen tissues of advanced gastric
carcinomas (14 intestinal type and 14 diffuse type)
and corresponding adjacent non-neoplastic tissues
for Western blot analysis. Twenty-two paraffin
embedded gastric carcinoma tissues were also
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used for immunohistochemical staining. The
vascular invasion and nodal metastasis in gastric
carcinomas were examined. The age distribution
was between 45 and 65 years old, and male and
female ratio was 1.5 : 1.
Immunohistochemistry
Formalin fixed paraffin embedded tissue sections
of 4 m thickness were made and spread on μ
poly-L-lysine coated slides. The sections were
deparaffinized and hydrated in a graded series of
alcohol. Antigen retrieval was routinely performed
by immersing the sections in 0.01 M citrate buffer
(pH 6.0) in a pressure cooker by autoclaving for
15 minutes. Endogenous peroxidase activity was
blocked with 3% hydrogen peroxide for 15 minutes
and then incubated with primary antibody for 2
hours at room temperature. The primary antibody
used was rabbit polyclonal anti-15-PGDH (Cayman
Chemical, Ann Arbor, MI, USA, dilution 1:400).
Staining was done with a DAKO LSAB+kit labeled
with peroxidase (DakoCytomation, Carpinteria,
CA, USA) and developed with 3, 3'-diamino-
benzidine tetrahydrochloride (Zymed Labora-
tories, South San Franciso, CA, USA) as a chromo-
gen. Sections were counterstained for 3 minutes
with Mayer's hematoxylin and then mounted. As
a negative control, rabbit IgG isotype was used
instead of primary antibody.
Western blot analysis
Tissues were suspended in a lysis buffer [10 mM
Tris-HCl (pH 7.4), 1 mM EDTA, and 0.25 M
sucrose, 1% Triton X-100] supplemented with
Complete mini protease inhibitor mixture tablets
(Boehringer Mannheim, Mannheim, Germany) on
ice for 1 hour. After removal of cell debris by cen-
trifugation, protein concentration in cell lysates
was determined by BCA protein assay reagent
(Pierce, Rockford, IL, USA) with bovine serum
albumin as a standard. Forty g of protein were μ
resolved by 12% SDS-polyacrylamide gel electro-
phoresis and transferred to a nitrocellulose mem-
brane. The membranes were blocked with 5% skim
milk in Tris buffered saline (TBS) for 1 hour at
room temperature and probed overnight with
antibodies at 4°C. The antibodies used were anti-
15-PGDH (Cayman Chemical), anti-proliferating
cell nuclear antigen (PCNA, Santa Cruz Biotech-
nology, Santa Cruz, CA, USA) and anti- -actin β
(Santa Cruz Biotechnology). After washing with
TBS-0.05% Tween 20, the blots were treated with
horseradish peroxidase-conjugated anti-rabbit IgG
antibody (1 : 3000; Zymed Laboratories) for 1 hour
at room temperature. Western blots were develop-
ed by chemiluminescence (Pierce) and autoradio-
graphy was used for detection. Optical density was
measured by using Scion Image (Scion Corp.,
Frederick, MD, USA).
DNA extraction and methylation specific polymerase
chain reaction (MSP)
Using a DNA Mini kit (Qiagen, Hilden, Germany),
genomic DNA was isolated from 5 frozen tissues
of gastric carcinomas and corresponding adjacent
non-neoplastic tissues according to the manufac-
turer's instructions. DNA samples were modified
by sodium bisulfite as described previously.
19
Modified DNA was subjected to MSP. Briefly,
genomic DNA is modified with sodium bisulfite,
which converts all unmethylated cytosines to
uracils, while 5-methylcytosines remain unaltered.
Primers are designed to specifically amplify each
of the sequences based on these chemically induced
differences. The primers were as follows: unme-
thylated 15-PGDH (195 bp), sense 5-GGG TAT
AAA AGT TGT GGT TGT GT-3, antisense 5-AAA
AAA ATT TCC ACA ACT AAA CAC CA-3 and
methylated 15-PGDH (189 bp), sense 5-GTA TAA
AAG TCG CGG TCG CGC-3, antisense 5-AAA
TTT CCG CGA CTA AAC GCC G-3.
20 PCR con-
ditions were as follows: 94°C for 5 minutes, 30
amplification cycles (94°C for 1 minute, 65°C for
1 minute, 72°C for 1 minute), followed by an addi-
tional extension step at 72°C for 75 minutes. PCR
products were electrophoresed in 1% agarose gel
containing ethidium bromide and were photo-
graphed under ultraviolet light.
Statistical analysis
Pearson correlation and Mann-Whitney U test
were used. Values of p < 0.05 were regarded as sig-
nificant. Data were expressed as mean ± standard
deviation.15-PGDH in Gastric Carcinomas
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RESULTS
Adjacent non-neoplastic epithelial cells and
carcinoma cells showed similarly strong cytoplas-
mic immunoreactivity for 15-PGDH (Fig. 1A). No
difference was found between carcinomas and
non-neoplastic tissues. Western blot analysis was
done in order to verify the result of immuno-
histochemical staining. As shown in Fig. 1B, vari-
able sized proteins, including a molecular weight
of 25 kDa, were expressed in carcinoma and non-
neoplastic tissue. We performed Western blot
analysis to examine 15-PGDH expression in 28
gastric carcinomas and corresponding non- neo-
plastic tissues. The expression of 15-PGDH was
significantly higher in non-neoplastic tissues than
in carcinomas (Fig. 2, p < 0.05) and correlated in-
versely with the PCNA expression in gastric car-
cinomas (Fig. 3, p<0.05, R=-0.55). We examined the
relationship between 15-PGDH expression level
and vascular invasion and nodal metastasis in 22
cases of 28 gastric carcinomas to investigate the
biologic behavior of the enzyme. Expression of
15-PGDH did not correlate with degree of the
nodal metastasis and vascular invasion in gastric
carcinomas (Fig. 4, p > 0.05). A recent study sug-
gested epigenetic silencing of the enzyme by DNA
methylation.
17 Therefore, MSP was done in 5
Fig. 2. Western blot analysis of 15-PGDH in gastric
carcinomas (T) and corresponding non-neoplastic tissues
(N). The expression of 15-PGDH was significantly higher
in corresponding non-neoplastic tissues than in car-
cinomas (p < 0.05). Forty g of protein was resolved by μ
10% SDS-polyacrylamide gel electrophoresis and transfer-
red to a nitrocellulose membrane. The bottom represents
-actin, which was used as a loading control. 15-PGDH, β
15-hydroxyprostaglandin dehydrogenase.
Fig. 3. Western blot analysis of 15-PGDH and PCNA in
gastric carcinomas. 15-PGDH expression was inversely
correlated with PCNA expression in gastric carcinomas (p
< 0.05, R = - 0.55). Forty g of protein was separated by μ
10% SDS-polyacrylamide gel electrophoresis and transfer-
red to a nitrocellulose membrane. The bottom represents
-actin, which was used as a loading control. 15-PGDH, β
15-hydroxyprostaglandin dehydrogenase; PCNA, prolife-
rating cell nuclear antigen.
Fig. 1. Immunohistochemical staining and Western blot
analysis of 15-PGDH in gastric carcinomas (T) and cor-
responding non-neoplastic tissue (N). (A) 15-PGDH was
strongly expressed in both the cytoplasm of carcinoma
cells and non-neoplastic mucosal epithelial cells. (B) Forty
g of protein was resolved by 10% SDS-polyacrylamide μ
gel electrophoresis and transferred to a nitrocellulose
membrane. 15-PGDH, 15-hydroxyprostaglandin dehydro-
genase
B ATae Jung Jang, et al.
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gastric carcinomas with variable expression of the
enzyme. As shown in Fig. 5, we could not detect
the promoter methylation of 15-GDH in two
gastric carcinomas with negligible expression of
the enzyme (T1 and T3).
DISCUSSION
In this study, we observed that 15-PGDH
expression was significantly decreased in gastric
carcinomas compared to corresponding non-neo-
plastic tissues, and that the promoter hyper-
methylation of 15-PGDH gene was not detected in
carcinomas with negligible expression of the
enzyme.
A number of studies have reported up-regula-
tion of COX-2, the rate-limiting enzyme in PG
biosynthesis, in gastric carcinomas and during
gastric carcinogenesis,
8-11 but the expression of 15-
PGDH, the key enzyme responsible for the bio-
logical inactivation of PG, in gastric carcinoma has
not been studied in detail. Moreover, the results
of 15-PGDH expression in 2 recent studies are
contrary to each other.
14,18 Therefore, we analyzed
the expression of the enzyme by immunohische-
mical staining. 15-PGDH was well expressed in both
gastric carcinoma cells and adjacent gastric mucosal
epithelial cells, however, there was no difference
between carcinomas and non-neoplastic tissues.
On, Western blot analysis, variable sized proteins,
including a molecular weight of 25 kDa, were ex-
pressed in carcinoma and non-neoplastic tissue.
This may explain the result that immunohistoche-
mistry did not show any difference in 15-PGDH
expression between carcinomas and non-neoplastic
tissues, and also the recent immunohistochemical
study that 15-PGDH expression was not altered in
gastric carcinomas.
18 Therefore, immunohistoche-
mical analysis was unable to reveal the difference
of 15-PGDH expression level between carcinoma
and non-neoplastic tissue. We performed Western
blot analysis to examine 15-PGDH expression
Fig. 4. Correlation between 15-PGDH expression, nodal
metastasis and vascular invasion in gastric carcinomas.
Expression of 15-PGDH was not related to the nodal meta-
stasis and vascular invasion in gastric carcinomas (p >
0.05). 15-PGDH, 15-hydroxyprostaglandin dehydrogenase.
Fig. 5. Western blot analysis of 15-PGDH in gastric carcinomas and methylation specific PCR with methylated 15-PGDH
primer sets (M) and unmethylated 15-PGDH primer sets (U) in gastric carcinomas. The promoter methylation of
15-PGDH was not observed in 2 gastric carcinomas (T1 and T3) with negligible expression of the enzyme. 15-PGDH,
15-hydroxyprostaglandin dehydrogenase.15-PGDH in Gastric Carcinomas
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level, and found that the expression of 15-PGDH
was significantly higher in non-neoplastic tissues
than in carcinomas and inversely correlated with
PCNA expression in gastric carcinomas. Similarly,
15-PGDH expression has been found to be highly
expressed in normal colonic epithelia, but nearly
undetectable in colon carcinomas.
13,14 In addition,
15-PGDH transcript is decreased in gastric carcino-
mas compared with non-neoplastic gastric tissues.
14 Recent studies demonstrated 15-PGDH to have
tumor suppressor activity in colon, lung and breast
carcinoma.
13-17 These findings suggest that 15-
PGDH has tumor suppressor activity also in
gastric carcinoma.
Methylation of 15-PGDH promoter in breast and
prostate carcinoma cells and tissues was shown.
17,20
In prostate carcinoma cells, CpG methylation of
PGDH was not accompanied by decreased gene
expression, and expression was even induced in
3 prostate carcinoma samples, clearly showing
CpG methylation.
20 These results indicate that CpG
methylation of a promoter should not be interpret-
ed as a proof of its transcriptional repression. In
this study, we did not detect hypermethylation of
the gene promoter in carcinomas with negligible
expression of the enzyme. The altered regulation
of genes through up-regulation of zinc-finger
transcriptional repressors, such as ZEB1, Slug, and
Snail, is increasingly being recognized as an
important mechanism in carcinoma progression.
21
In human colon cancers, elevated Snail expression
correlates well with down-regulation of 15-
PGDH.
22 In the future, relationship between the
repressors and 15-PGDH expression should be
analyzed in gastric carcinoma.
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